TRVI Trevi Therapeutics Inc.

2.93
+0.03  (+1%)
Previous Close 2.9
Open 2.94
52 Week Low 1.33
52 Week High 8.5
Market Cap $53,855,715
Shares 18,380,790
Float 5,569,750
Enterprise Value $14,092,291
Volume 99,902
Av. Daily Volume 128,086
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Nalbuphine ER - PRISM
Prurigo Nodularis
Phase 2/3
Phase 2/3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Nalbuphine ER
Chronic cough - Idiopathic pulmonary fibrosis (IPF)
Phase 2
Phase 2
Phase 2 trial has restarted following halt due to COVID-19 - October 21, 2020.

Latest News

  1. NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021.

    Presentation Time: 4:20 p.m. ET

    A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events' in the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30…

    NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021.

    Presentation Time: 4:20 p.m. ET

    A live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events' in the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.

    The Company's corporate presentation is posted to its website in the ‘Investors & News' section under ‘News & Events'.

    About Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with IPF.

    Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

    About HADUVIO

    Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

    Investor Contact

    Chris Seiter, Chief Financial Officer

    Trevi Therapeutics, Inc.

    203-304-2499

    Media Contact

    Rosalia Scampoli

    914-815-1465



    Primary Logo

    View Full Article Hide Full Article
  2. Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

    NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi's senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications.

    "I am happy to welcome Bill to our executive leadership team," said Jennifer L. Good, President and Chief Executive Officer…

    Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

    NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi's senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications.

    "I am happy to welcome Bill to our executive leadership team," said Jennifer L. Good, President and Chief Executive Officer of Trevi. "Bill has a proven track record of success in developing and managing highly effective product development teams and progressing products through all phases of clinical development and regulatory milestones, including multiple approvals. Bill's extensive experience in pharmaceutical product development will be extremely valuable as we complete enrollment and report top-line data from our Phase 2b/3 trial for chronic pruritus in patients with prurigo nodularis and our Phase 2 trial for chronic cough in patients with IPF and prepare for the next steps in development for both of these programs."

    Dr. Forbes joins Trevi with over 30 years of experience in pharmaceutical product development. Before joining Trevi, he served as Founder, President and CEO of Vivelix Pharmaceuticals. Prior to Vivelix, Dr. Forbes held multiple senior leadership positions throughout his career, including Chief Development Officer for Salix Pharmaceuticals where he was responsible for the development of Xifaxan (rifaximin) in multiple indications. Dr. Forbes' contributions at Salix were instrumental in guiding 12 FDA approvals. He holds a Pharm.D. from Creighton University.

    "This is an exciting time to join Trevi with two late-stage development programs of Haduvio ongoing which could help to meet the needs' of patients suffering from serious conditions with no approved therapies," said Dr. Forbes. "I am impressed with Trevi's highly skilled professionals and look forward to working with the team to achieve key near-term product development goals this year."

    About Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with IPF.

    Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

    About HADUVIO

    Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the expected timing of enrollment and for reporting top-line data from, Trevi's Phase 2b/3 PRISM trial of Haduvio in patients with prurigo nodularis; Trevi's business plans and objectives, including future plans or expectations for Trevi's product candidates; and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and ongoing and planned clinical trials; uncertainties regarding the scope, timing and severity of the COVID-19 pandemic, the impact of the COVID-19 pandemic on Trevi's clinical operations and actions taken in response to the pandemic; uncertainties regarding Trevi's ability to execute on its strategy; the risk that positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; potential regulatory developments in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results; as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Investor Contact

    Chris Seiter, Chief Financial Officer

    Trevi Therapeutics, Inc.

    203-304-2499

    Media Contact

    Rosalia Scampoli

    914-815-1465



    Primary Logo

    View Full Article Hide Full Article
  3. PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis 

    Exceeds Halfway Enrollment Milestone

    Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 Restrictions

    Cash Position Expected to Fund Operations into the First Half of 2022

    NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.

    "We are pleased with the continued progress of our clinical development programs," said Jennifer…

    PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis 

    Exceeds Halfway Enrollment Milestone

    Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post-COVID-19 Restrictions

    Cash Position Expected to Fund Operations into the First Half of 2022

    NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2020, as well as business updates.

    "We are pleased with the continued progress of our clinical development programs," said Jennifer L. Good, President and CEO of Trevi Therapeutics. "We recently announced significant developments in both of our ongoing clinical trials by surpassing halfway enrollment in our PRISM trial and enrolling the first new subject in our chronic cough trial in IPF since the study resumed after pausing due to COVID restrictions. We are focused on completing enrollment in both trials and preparing for the next steps in the development of Haduvio."

    Key Business Updates

    • Phase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with prurigo nodularis: The Company has enrolled approximately 190 subjects in the trial and reaffirms its guidance that it expects to complete enrollment in the third quarter of 2021 and to report top-line data in the fourth quarter of 2021.



    • Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF): The Company resumed screening and enrolling patients in the trial following the pause in the trial due to COVID-19. The Company amended the study protocol to require fewer in-person visits by subjects as well as fewer procedures in order to facilitate the completion of the trial in an at-risk patient population for COVID-19. Additionally, the Company is assessing additional study sites in Germany which could potentially accelerate enrollment and reduce the risks inherent with single-country recruitment during the COVID-19 pandemic.

    Third Quarter 2020 Financial Highlights

    Cash position: As of September 30, 2020, the Company had total cash and cash equivalents of $53.3 million, compared to $57.3 million as of December 31, 2019. During the third quarter of 2020, the Company received $14.0 million in proceeds from a term loan with Silicon Valley Bank and sold approximately $2.5 million of common stock under the Company's ATM program. The Company expects its cash position will fund operations into the first half of 2022.

    Research and development (R&D) expenses: R&D expenses for the third quarter of 2020 were $4.8 million compared to $5.7 million in the same period in 2019. The decrease was primarily due to decreased activity in the Company's Phase 2 trial in chronic cough in patients with IPF due to the pausing of enrollment and treatment of patients as a result of the COVID-19 pandemic as well as decreased activity with the completion of the Company's Phase 1b trial in patients with chronic liver disease.

    General and administrative (G&A) expenses: G&A expenses for the third quarter of 2020 were $2.4 million compared to $2.0 million in the same period in 2019. The increase was primarily due to an increase in stock-based compensation expenses and an increase in consulting fees.

    Net loss: For the third quarter of 2020, the Company reported a net loss of $7.4 million, compared to a net loss of $7.4 million in the same period in 2019.

    Conference Call

    As previously announced, the Company will host a conference call and webcast today, November 11, 2020 at 4:30 p.m. ET. To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 9375955. A live audio webcast will be accessible from the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.         

    About Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

    Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

    About HADUVIO

    Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the impact of the COVID-19 pandemic on Trevi's clinical trials, business and operations; the expected timing of enrollment and for reporting top-line data from, Trevi's Phase 2b/3 PRISM trial of Haduvio in patients with prurigo nodularis; Trevi's business plans and objectives, including future plans or expectations for Trevi's product candidates and expectations regarding Trevi's uses and sufficiency of capital; and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and ongoing and planned clinical trials; uncertainties regarding the scope, timing and severity of the COVID-19 pandemic, the impact of the COVID-19 pandemic on Trevi's clinical operations and actions taken in response to the pandemic; uncertainties regarding Trevi's ability to execute on its strategy; the risk that positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; potential regulatory developments in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results; as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Trevi Therapeutics, Inc.

    Selected Balance Sheet Data

    (unaudited)

    (amounts in thousands)

     September 30,

    2020
     December 31,

    2019
        
    Cash and cash equivalents$53,293 $57,313
    Working capital 49,106 54,353
    Total assets 55,879 60,001
    Total debt 13,798 ──
    Stockholders' equity 35,618 54,545

    Trevi Therapeutics, Inc.

    Selected Statement of Operations Data

    (unaudited)

    (amounts in thousands)

     Three Months Ended

    September 30,
     Nine Months Ended

    September 30,
     2020 2019 2020 2019
            
    Operating expenses:       
    Research and development$4,828  $5,650  $15,768  $14,516 
    General and administrative 2,416   2,000   7,528   5,363 
    Total operating expenses 7,244   7,650   23,296   19,879 
    Loss from operations (7,244)  (7,650)  (23,296)  (19,879)
    Other income (expense), net (145)  280   26   352 
    Loss before income tax benefit (7,389)  (7,370)  (23,270)  (19,527)
    Income tax benefit 11   5   35   14 
    Net loss$(7,378) $(7,365) $(23,235) $(19,513)

    Investor Contact

    Chris Seiter, Chief Financial Officer

    Trevi Therapeutics, Inc.

    203-304-2499

    Media Contact  

    Rosalia Scampoli

    914-815-1465

    Primary Logo

    View Full Article Hide Full Article
  4. NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020.

    Presentation Time: 10:00 a.m. ET

    A live webcast of the presentation can be accessed by visiting ‘News & Events' in the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following…

    NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020.

    Presentation Time: 10:00 a.m. ET

    A live webcast of the presentation can be accessed by visiting ‘News & Events' in the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.

    The Company's corporate presentation is posted to its website in the ‘Investors & News' section under ‘News & Events'.

    About Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

    Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

    About HADUVIO

    Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

    Investor Contact

    Chris Seiter, Chief Financial Officer

    Trevi Therapeutics, Inc.

    203-304-2499

    Media Contact  

    Rosalia Scampoli

    914-815-1465

    Primary Logo

    View Full Article Hide Full Article
  5. NEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 11, 2020, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2020.

    To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 9375955. A live audio webcast will be accessible from the ‘Investors & News' section on the…

    NEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 11, 2020, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2020.

    To participate in the live conference call by phone, please dial (866) 360-5746 (domestic) or (602) 563-8605 (international) and provide access code 9375955. A live audio webcast will be accessible from the ‘Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

    About Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is currently developing Haduvio for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of Haduvio, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.

    Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

    About HADUVIO

    Haduvio is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action also mitigates the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. Trevi intends to propose Haduvio as the trade name for the nalbuphine ER investigational product. Haduvio is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

    Investor Contact

    Chris Seiter, Chief Financial Officer

    Trevi Therapeutics, Inc.

    203-304-2499

    Media Contact  

    Rosalia Scampoli

    914-815-1465

            

    Primary Logo

    View Full Article Hide Full Article
View All Trevi Therapeutics Inc. News